Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Cyclophosphamide
Treatment for Chronic kidney disease due to glomerulonephritis
Typical Dosage: 0.5-1 g/m² IV monthly pulses OR 1-2 mg/kg/day orally
Effectiveness
80%
Safety Score
25%
Clinical Trials
150
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
0.5-1 g/m² IV monthly pulses OR 1-2 mg/kg/day orally
Time to Effect
2-6 weeks
Treatment Duration
3-6 months (induction)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$2,000
Side Effect Mgmt:$3,000
Total Annual:$6,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
2.2
Outcome-Based Costs
Cost per Responder
$8,125
Cost per Remission
$10,833
Comparison vs No treatment
Cost Difference
+$6,500/year
More expensive
QALY Difference
+2.20 QALYs
Better outcomes
Dominance
No dominance
Cyclophosphamide Outcomes
for Chronic kidney disease due to glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+60%
Common Side Effects
Bone marrow suppression
+65%
Infections
+30%
Hemorrhagic cystitis
+10%
Infertility
+20%
Nausea/vomiting
+45%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov